Worth reading
55In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
40000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise of stock acquisition rights with provisions for adjustment to the exercise price (monthly exercise status)
発行・処分する株式数40,000Shares
40,000 new shares
発行済株式総数
Exercise ratio subject to exercise restrictions: 0.20% (40,000 shares delivered across all series / 19,196,700 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise prices during the target month were ¥407.7, ¥331.2 and ¥296.1. Details of the adjustment clause and the lower limit: Not disclosed
Number of Stock Acquisition Rights
Exercise ratio relative to the total number issued: 0.51%. Unexercised stock acquisition rights were 76,503 as of the end of the month preceding the target month and 76,103 as of the end of the target month.
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc.
Most recent equity financing
Development Promotion Stock Acquisition Rights for docirbrutinib (AS-1763) with Exercise Price Adjustment Clause, issued on 17 February 2026
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise of stock acquisition rights with provisions for adjustment to the exercise price (monthly exercise status) |
| Number of shares to be issued or disposed of | 40,000 new shares |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 0.20% (40,000 shares delivered across all series / 19,196,700 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 20,612,469 shares (as of the end of the month preceding the target month) → Not disclosed |
| Exercise price | The exercise prices during the target month were ¥407.7, ¥331.2 and ¥296.1. Details of the adjustment clause and the lower limit: Not disclosed |
| Number of Stock Acquisition Rights | Exercise ratio relative to the total number issued: 0.51%. Unexercised stock acquisition rights were 76,503 as of the end of the month preceding the target month and 76,103 as of the end of the target month. |
| Procedures under the Corporate Code of Conduct | Describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc. |
| Most recent equity financing | Development Promotion Stock Acquisition Rights for docirbrutinib (AS-1763) with Exercise Price Adjustment Clause, issued on 17 February 2026 |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason given by the company.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.